Molecular profiling of cancer at the transcript level has become routine. Large-scale analysis
of proteomic alterations during cancer progression has been a more daunting task. Here, we …

DNA sequencing has identified recurrent mutations that drive the aggressiveness of prostate
cancers. Surprisingly, the influence of genomic, epigenomic, and transcriptomic …

To understand functional consequences of genetic and transcriptional aberrations in
prostate cancer, the proteomic changes during disease formation and progression need to …

Background Clinical management of the prostate needs improved prognostic tests and
treatment strategies. Because proteins are the ultimate effectors of most cellular reactions …

Prostate cancer remains the second leading cause of cancer death in American men and
there is an unmet need for biomarkers to identify patients with aggressive disease. In an …

Multiple, complex molecular events characterize cancer development and progression.
Deciphering the molecular networks that distinguish organ-confined disease from metastatic …

We used clinical tissue from lethal metastatic castration-resistant prostate cancer (CRPC)
patients obtained at rapid autopsy to evaluate diverse genomic, transcriptomic, and …

Prostate cancer displays considerable clinical, morphological, and biological heterogeneity.
Classical genetic techniques have provided only limited information about the pathogenesis …

The unpredictable behavior of prostate cancer presents a major clinical challenge during
patient management. In order to gain an insight into the molecular mechanisms associated …

Identifying the earliest somatic changes in prostate cancer can give important insights into
tumor evolution and aids in stratifying high-from low-risk disease. We integrated whole …